MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics, Inc. (BBOT)

|||

Balance Sheets Overview

Current Ratio
469.42%
Quick Ratio
469.42%
Cash Ratio
104.70%
Debt to Asset Ratio
14.23%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term marketable securities
    • Long-term marketable securities
    • Cash and cash equivalents
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued research and development...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
54,063
52,658
373,687
408,741
Short-term marketable securities
171,648
199,617
51,773
59,544
Receivables from related parties
661
146
386
226
Prepaid expense and other current assets
16,006
14,081
6,550
7,499
Total current assets
242,378
266,502
432,396
476,010
Long-term marketable securities
118,419
136,617
-
-
Property and equipment, net
878
938
956
827
Operating lease right-of-use asset
2,104
2,218
2,330
2,440
Other non-current assets
12,795
11,239
12,567
5,384
Restricted cash
132
132
132
132
Total assets
376,706
417,646
448,381
484,793
Accounts payable
6,728
12,090
1,374
3,650
Accrued compensation and benefits
4,387
2,018
5,746
4,489
Accrued research and development liabilities
36,841
25,920
25,951
24,107
Accrued professional services
1,943
1,433
674
2,091
Payables to related parties
986
716
534
691
Operating lease liability, current
554
538
522
506
Other accrued liabilities
195
545
240
178
Participation right liability
-
-
0
0
Total current liabilities
51,634
43,260
35,041
35,712
Operating lease liability, noncurrent
1,960
2,106
2,244
2,381
Total liabilities
53,594
45,366
37,285
38,093
Preference stock, value-Redeemable Convertible Preferred Stock
0
0
0
0
Preference stock, value-Preferred Stock
0
0
0
0
Common stock, 0.0001 par value 500,000,000 shares authorized as of june 30, 2026 and december 31, 2025, respectively 80,088,931 and 79,991,768 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
8
8
8
8
Additional paid-in capital
779,190
771,926
767,639
764,426
Accumulated deficit
-455,127
-398,673
-356,567
-317,770
Accumulated other comprehensive income (loss)
-959
-981
16
36
Total stockholders' equity
323,112
372,280
411,096
446,700
Total liabilities, redeemable convertible preferred stock, and stockholders' equity
376,706
417,646
448,381
484,793
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term marketablesecurities$171,648K Cash and cashequivalents$54,063K Prepaid expense andother current assets$16,006K Receivables from relatedparties$661K Total current assets$242,378K Long-term marketablesecurities$118,419K Other non-currentassets$12,795K Operating leaseright-of-use asset$2,104K Property and equipment,net$878K Restricted cash$132K Total assets$376,706K Total liabilities,redeemable convertible...$376,706K Total stockholders'equity$323,112K Total liabilities$53,594K Accumulated deficit-$455,127K Accumulated othercomprehensive income (loss)-$959K Additional paid-in capital$779,190K Total currentliabilities$51,634K Operating leaseliability, noncurrent$1,960K Common stock, 0.0001par value...$8K Accrued research anddevelopment liabilities$36,841K Accounts payable$6,728K Accrued compensationand benefits$4,387K Accrued professionalservices$1,943K Payables to relatedparties$986K Operating leaseliability, current$554K Other accruedliabilities$195K